Arrow Financial’s Vertex Pharmaceuticals VRTX Stock Holding History

Arrow Financial’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.34M	Sell	2,994 -91	-3%	-$42.4K	0.13%	86
2025 Q4	$1.4M	Sell	3,085 -152	-5%	-$65.5K	0.14%	86
2025 Q3	$1.27M	Sell	3,237 -65	-2%	-$27.2K	0.13%	88
2025 Q2	$1.47M	Sell	3,302 -83	-2%	-$38.2K	0.15%	80
2025 Q1	$1.64M	Sell	3,385 -2,220	-40%	-$1.03M	0.18%	78
2024 Q4	$2.26M	Buy	5,605 +10	+0.2%	+$4.63K	0.21%	73
2024 Q3	$2.6M	Sell	5,595 -411	-7%	-$197K	0.24%	71
2024 Q2	$2.82M	Buy	6,006 +315	+6%	+$137K	0.27%	68
2024 Q1	$2.38M	Buy	5,691 +2,342	+70%	+$990K	0.24%	71
2023 Q4	$1.36M	Buy	3,349 +1,537	+85%	+$568K	0.14%	90
2023 Q3	$630K	Buy	1,812 +1,492	+466%	+$522K	0.07%	116
2023 Q2	$113K	Buy	320 +12	+4%	+$4.04K	0.01%	170
2023 Q1	$97K	Sell	308 -2	-0.6%	-$600	0.01%	179
2022 Q4	$90K	Sell	310 -5	-2%	-$1.52K	0.01%	181
2022 Q3	$91K	Hold	315	–	–	0.01%	179
2022 Q2	$89K	Hold	315	–	–	0.01%	178
2022 Q1	$82K	Hold	315	–	–	0.01%	192
2021 Q4	$69K	Hold	315	–	–	0.01%	196
2021 Q3	$57K	Hold	315	–	–	0.01%	207
2021 Q2	$63K	Hold	315	–	–	0.01%	200
2021 Q1	$67K	Hold	315	–	–	0.01%	197
2020 Q4	$75K	Hold	315	–	–	0.01%	183
2020 Q3	$86K	Sell	315 -20	-6%	-$5.52K	0.02%	173
2020 Q2	$97K	Hold	335	–	–	0.02%	179
2020 Q1	$79K	Buy	335 +15	+5%	+$3.44K	0.02%	186
2019 Q4	$70K	Hold	320	–	–	0.01%	199
2019 Q3	$54K	Sell	320 -10	-3%	-$1.77K	0.01%	210
2019 Q2	$61K	Hold	330	–	–	0.01%	214
2019 Q1	$61K	Hold	330	–	–	0.01%	213
2018 Q4	$55K	Hold	330	–	–	0.01%	205
2018 Q3	$64K	Hold	330	–	–	0.01%	211
2018 Q2	$56K	Hold	330	–	–	0.01%	199
2018 Q1	$54K	Hold	330	–	–	0.01%	205
2017 Q4	$49K	Buy	330 +30	+10%	+$4.44K	0.01%	209
2017 Q3	$46K	Hold	300	–	–	0.01%	215
2017 Q2	$39K	Hold	300	–	–	0.01%	227
2017 Q1	$33K	Hold	300	–	–	0.01%	233
2016 Q4	$22K	Hold	300	–	–	0.01%	254
2016 Q3	$26K	Hold	300	–	–	0.01%	245
2016 Q2	$26K	Hold	300	–	–	0.01%	245
2016 Q1	$24K	Sell	300 -7	-2%	-$633	0.01%	252
2015 Q4	$39K	Buy	307 +7	+2%	+$845	0.01%	224
2015 Q3	$31K	Buy	+300	New	+$38.5K	0.01%	220
2014 Q2	–	Sell	-195	Closed	-$14K	–	362
2014 Q1	$14K	Hold	195	–	–	﹤0.01%	269
2013 Q4	$14K	Buy	195 +165	+550%	+$11.5K	﹤0.01%	257
2013 Q3	$2K	Sell	30 -30	-50%	-$2.39K	﹤0.01%	339
2013 Q2	$5K	Buy	+60	New	+$4.42K	﹤0.01%	298

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Arrow Financial's VRTX Position: Q1 2026 in Review

Arrow Financial reduced its Vertex Pharmaceuticals (VRTX) stake by 2.9% in Q1 2026, selling an estimated $42.4K and leaving 2,994 shares worth $1.34M. The position accounts for 0.13% of the portfolio, ranked #86.

Arrow Financial first reported a position in VRTX in Q2 2013 and has held it in 47 quarters since. The position peaked at $2.82M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Arrow Financial held 2,994 shares of Vertex Pharmaceuticals worth $1.34M as of Q1 2026.
Arrow Financial sold 91 Vertex Pharmaceuticals shares in Q1 2026, an estimated $42.4K.
Vertex Pharmaceuticals made up 0.13% of Arrow Financial's portfolio in Q1 2026, its #86 holding.
Arrow Financial first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 47 quarters since.
Arrow Financial's Vertex Pharmaceuticals position peaked at $2.82M in Q2 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Arrow Financial's 13F filing for Q1 2026, filed 11 May 2026.